JIMON GROUP
An independent research space.
Knowledge. Science. Progress.

An independent research platform on JIMON GROUP: history, documents, scientific foundations, manufacturing and products.
An independent research space.
Knowledge. Science. Progress.

When people first encounter the name JIMON GROUP, they usually see one of two descriptions: either a claim that it is a “largest corporation in the field of traditional Chinese medicine with a 33-year history,” or references to a company operating through network marketing. At first glance, the picture seems straightforward. But checking the sources immediately raises questions: why do Chinese state registries give one registration date while company materials give another? What lies behind claims about “companies with a 450-year history”? How strong is the scientific foundation, and which products actually have registration certificates?
This article brings together the available verifiable information about JIMON GROUP, separates confirmed facts from marketing claims, and presents the company as a complex system connecting the long traditions of Chinese medicine with modern manufacturing, science and international business.

JIMON GROUP is the international name of the Chinese company 金木集团有限公司 (Jinmu Group Co., Ltd.), formerly known as Hebei Jinmu Pharmaceutical Group Co., Ltd. The group specializes in traditional Chinese medicine (TCM), the manufacture of medicines, dietary supplements, cosmetics and health food products.
Confirmed facts:
Company claims:
This article provides an overview of JIMON GROUP: its history, legal structure, manufacturing capacity, product portfolio, technologies, scientific development, ingredients, relationship with traditional Chinese medicine, certificates, key events and marketing system.
Read more about the history, products, technology and documents in the reading paths above.
JIMON GROUP operates at the intersection of three significant fields:

Understanding the actual structure, capabilities and limitations of JIMON GROUP matters to consumers as well as researchers studying the TCM and network-marketing markets.
JIMON GROUP states that it was founded in 1993 in Anguo, Hebei Province — a city known in China as the “millennial capital of medicinal herbs,” with a history of more than a thousand years in the trade and production of medicinal plant materials. The company presents itself not as a startup but as a continuation of ancient traditions. According to its claims, the group has acquired enterprises with histories of traditional-medicine production spanning 125, 305, 357 and even 450 years.
Chinese corporate registries, including Tianyancha and Qichacha, indicate that the current legal entity, 金木集团有限公司 (Jinmu Group Co., Ltd.), was registered in 2004. Until 2016, the company was known as 河北金木药业集团有限公司 (Hebei Jinmu Pharmaceutical Group Co., Ltd.).
This kind of discrepancy is not unusual for Chinese companies: the stated “founding” date may refer to the founder’s start in business or to the history of acquired enterprises rather than the registration of the current legal entity.
Key milestones reported in available sources:
The difference between 1993 and 2004 most likely reflects two distinct milestones: the founder’s start in the medicinal-herb business in 1993 and the registration of a formal corporate entity in 2004. Claims about “companies with a 450-year history” require separate investigation: the sources currently available do not make it possible to identify these enterprises precisely or confirm the continuity of their traditions. This is a subject for a dedicated research article.
According to company statements and industry publications, the group is organized around a model of “one research centre plus six production bases”:
The group includes subsidiaries, among them 保定中药制药有限公司 (Baoding Chinese Medicine Pharmaceutical Co., Ltd.), a company specializing in the production of patented traditional Chinese medicines.
According to official announcements and Chinese media publications, JIMON GROUP is represented in 18 countries worldwide:
Subsidiaries, representative offices and, in some cases, production facilities operate in these countries.
Company statements and industry sources: JIMON GROUP owns or controls medicinal-herb plantations covering more than 17,400 mu (approximately 1,160 hectares) across different regions of China:
The company says cultivation follows GAP (Good Agricultural Practice) standards, which set practices intended to support the quality and safety of plant-based raw materials. Media reports state that the company cooperates with more than 1,400 farming households, providing technology and training.
JIMON GROUP operates in several product categories:
JIMON GROUP says it combines classical TCM formulas with modern manufacturing and analytical technologies.

JIMON GROUP’s scientific activities are built around a multi-level system of partnerships and in-house research structures.

In 2026, an article reporting research on Guanxinjing was published in the Tianjin Journal of Traditional Chinese Medicine. The researchers identified multiple chemical compounds in the product and described a multi-component, multi-target mechanism of action in cardiovascular conditions.
JIMON GROUP products use a broad range of ingredients, most of which are associated with the traditional Chinese medicine pharmacopoeia:
The company states that ingredient quality is controlled at every stage, from seed selection and cultivation on its plantations to incoming-material checks and final testing of finished products.

Traditional Chinese medicine is not merely a source of formulas for JIMON GROUP; it is presented as the conceptual foundation of the company’s activities.
JIMON GROUP illustrates a contemporary stage in the development of traditional Chinese medicine: a transition from predominantly empirical experience towards a system that combines classical principles with evidence, modern technologies and international quality standards. At the same time, many TCM formulas have a long history of use, but not all have undergone a full course of clinical testing under the standards of evidence-based medicine.
Table
| Document / certificate | Status | Source |
|---|---|---|
| Direct-selling licence (China’s Ministry of Commerce) | Confirmed, 2015 | Official data |
| ISO 9001 (quality management system) | Confirmed | Industry publications, company information |
| ISO 22000 (food safety) | Confirmed | Industry publications, company information |
| CNAS laboratory accreditation | Confirmed | Company information and industry media |
| HALAL certification (Indonesia) | Confirmed for more than 50 products | Hebei Daily publications |
| Product registration in Canada | Confirmed for 9 products | Hebei Daily publications |
| Product registration in Singapore and Malaysia | Confirmed | Official announcements |
| Chinese national patents | Confirmed: 30 | Company website |
| Registration certificates for medicines | Confirmed: more than 100 | Company website |
JIMON GROUP uses a combined distribution model in which direct selling (network marketing) is a key element.
The network-marketing model can help a company scale sales rapidly in new markets without major investment in traditional retail infrastructure. Consumers should nevertheless distinguish between:
It is important to note that a Chinese licence does not automatically authorize the same business model in every country where the company operates. Each jurisdiction has its own rules governing direct selling.
JIMON GROUP is more than a seller of dietary supplements through network marketing. It is a complex structure combining:
At the same time, the company remains a subject that warrants further study. Many of its statements need additional verification against primary documents, and product efficacy requires independent research. Our resource will continue this work in future publications.


If you have a document, source or detail that could add to or clarify this picture, you can send it to the author for review. Sometimes a single page from an original document advances an investigation more than ten additional paragraphs of analysis.
You are welcome to ask any question.
This material is an independent research project. The website is not an official representative of JIMON GROUP and does not receive funding from the company. Statements are separated into confirmed facts, claims made by the company itself and editorial analysis. We aim for the highest possible accuracy and will update this material as new verifiable information becomes available.
Browse the site’s topic archives.